Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 1, 2002, Pages 203-210

  Peterson, M L ^a   Hovde, L B ^a   Wright, D H ^a   Brown, G H ^a   Hoang, A D ^a   Rotschafer, J C ^a  

^a REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; CONCENTRATION RESPONSE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MODEL; PERFORMANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; REGRESSION ANALYSIS; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BACTEROIDES FRAGILIS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; TIME FACTORS;

EID: 0036136653     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.1.203-210.2002     Document Type: Article

References (28)

1. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species
2. Comparative in vitro activities of trovafloxacin (CP-99,219) against 211 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections
3. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
4. Pharmacodynamic properties of antibiotics: Application to drug monitoring and dosage regimen design
5. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
6. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: Review of current information on efficacy and safety
7. In vitro activity of gemifloxacin (SB 265805) against anaerobes
8. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
9. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
10. Bay 12-8039, a new 8-methoxyquinolone: Comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria
11. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model
12. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates
13. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
14. Wound and intraabdominal infections: Microbiological considerations and approaches to treatment
15. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone
16. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure
17. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
18. Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model
19. What have we learned from pharmacokinetic and pharmacodynamic theories?
20. Mathematical examination of dual individualization principles: Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin
21. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996
22. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes
23. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patient during therapy
24. Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography
25. Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads
26. Evaluation of the activity of temafloxacin versus Bacteroides fragilis using an in vitro pharmacodynamic system